Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

orifarm ab - betametasondipropionat; kalcipotriolmonohydrat - salva - 50 mikrogram/g + 0,5 mg/g - betametasondipropionat 0,643 mg aktiv substans; kalcipotriolmonohydrat 0,052 mg aktiv substans

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - betametasondipropionat; kalcipotriolmonohydrat - salva - 50 mikrogram/g + 0,5 mg/g - kalcipotriolmonohydrat 0,052 mg aktiv substans; betametasondipropionat 0,643 mg aktiv substans

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - betametasondipropionat; kalcipotriolmonohydrat - salva - 50 mikrogram/g + 0,5 mg/g - kalcipotriolmonohydrat 0,052 mg aktiv substans; betametasondipropionat 0,643 mg aktiv substans

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - betametasondipropionat; kalcipotriolmonohydrat - salva - 50 mikrogram/g + 0,5 mg/g - kalcipotriolmonohydrat 0,052 mg aktiv substans; betametasondipropionat 0,643 mg aktiv substans

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - betametasondipropionat; kalcipotriolmonohydrat - salva - 50 mikrogram/g + 0,5 mg/g - betametasondipropionat 0,643 mg aktiv substans; kalcipotriolmonohydrat 0,052 mg aktiv substans

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

archie samiel s.r.o. - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiska medel - clopidogrel är indicerat hos vuxna för förebyggande av atherothrombotic händelser i:patienter som lider av hjärtinfarkt (från några dagar till mindre än 35 dagar), ischemisk stroke (från 7 dagar till mindre än 6 månader) eller etablerad perifer arteriell sjukdom, patienter som lider av akuta koronara syndrom:icke-st-segment-höjd akuta koronara syndrom (instabil angina eller icke-q-våg-myocardial infarkt), inklusive patienter som genomgår en stent placering efter perkutan koronar intervention, i kombination med acetylsalicylsyra (asa);st-segment-höjd akut hjärtinfarkt, i kombination med asa i medicinskt behandlade patienter berättigade till trombolysbehandling.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetin delta - kidney failure, chronic; anemia - antianemiska preparat - dynepo är indicerat för behandling av symptomatisk anemi associerad med kroniskt njursvikt (crf) hos vuxna patienter. det kan användas till patienter i dialys och hos patienter som inte är i dialys.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

dynavax gmbh - hepatit b-ytantigen - hepatit b - vacciner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vacciner - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.